Predicting Poor Overall Survival in Patients with Newly Diagnosed Multiple Myeloma and Standard-Risk Cytogenetics Treated with Novel Agents

被引：0
|
作者：
Binder, Moritz [1 ]
Rajkumar, S. Vincent [2 ]
Ketterling, Rhett P. [3 ]
Dispenzieri, Angela [2 ]
Lacy, Martha Q. [2 ]
Gertz, Morie A. [2 ]
Buadi, Francis K. [2 ]
Hayman, Suzanne R. [2 ]
Hwa, Yi L. [2 ]
Zeldenrust, Steven R. [2 ]
Lust, John A. [2 ]
Russell, Stephen J. [2 ]
Leung, Nelson [2 ]
Kapoor, Prashant [2 ]
Go, Ronald S. [2 ]
Gonsalves, Wilson I. [2 ]
Kyle, Robert A. [2 ]
Kumar, Shaji K. [2 ]
机构：
[1] Mayo Clin, Dept Internal Med, Rochester, MN USA
[2] Mayo Clin, Div Hematol, Rochester, MN USA
[3] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.3255.3255
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3255
引用
收藏
页数：5
相关论文
共 50 条
  • [31] Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population
    Sorrig, Rasmus
    Klausen, Tobias W.
    Salomo, Morten
    Vangsted, Annette J.
    Frolund, Ulf Christian
    Andersen, Kristian T.
    Klostergaard, Anja
    Helleberg, Carsten
    Pedersen, Robert S.
    Pedersen, Per T.
    Helm-Petersen, Sissel
    Teodorescu, Elena Manuela
    Preiss, Birgitte
    Abildgaard, Niels
    Gimsing, Peter
    PLOS ONE, 2017, 12 (12):
  • [32] IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM)
    Kroenke, J.
    Kuchenbauer, F.
    Kull, M.
    Teleanu, V.
    Bullinger, L.
    Bunjes, D.
    Greiner, A.
    Kolmus, S.
    Koepff, S.
    Schreder, M.
    Muegge, L-O
    Straka, C.
    Engelhardt, M.
    Doehner, H.
    Einsele, H.
    Bassermann, F.
    Bargou, R.
    Knop, S.
    Langer, C.
    LEUKEMIA, 2017, 31 (06) : 1363 - 1367
  • [33] Gene expression profiling predicts relapse-free and overall survival in newly diagnosed myeloma patients treated with novel therapies
    Manasanch, Elisabet E.
    Berrios, David
    Fountain, Eric
    Claussen, Catherine M.
    Chuang, Tammy
    Kaufman, Gregory
    Amini, Behrang
    Bashir, Qaiser
    Nieto, Yago
    Qazilbash, Muzaffar
    Patel, Krina
    Thomas, Sheeba K.
    Weber, Donna M.
    Berkova, Zuzana
    Toruner, Gokce
    Lin, Pei
    Feng, Lei
    Lee, Hans C.
    Orlowski, Robert Z.
    Kunacheewa, Chutima
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 192 (04) : e115 - e120
  • [34] Predicting Risk of Infection in Patients with Newly Diagnosed Multiple Myeloma: Utility of Immune Profiling
    Teh, Benjamin W.
    Harrison, Simon J.
    Allison, Cody Charles
    Slavin, Monica A.
    Spelman, Tim
    Worth, Leon J.
    Thursky, Karin A.
    Ritchie, David
    Pellegrini, Marc
    FRONTIERS IN IMMUNOLOGY, 2017, 8
  • [35] Predictors of inferior clinical outcome in patients with standard-risk multiple myeloma
    Badar, Talha
    Srour, Samer
    Bashir, Qaiser
    Shah, Nina
    Al-Atrash, Gheath
    Hosing, Chitra
    Popat, Uday
    Nieto, Yago
    Orlowski, Robert Z.
    Champlin, Richard
    Qazilbash, Muzaffar H.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2017, 98 (03) : 263 - 268
  • [36] Nontransplant Treatment Outcomes with Generic Novel Agents in Newly Diagnosed Multiple Myeloma Patients
    Nair, Chandran K.
    Raghavan, Vineetha
    Bhattacharjee, Atanu
    Babu, Satheesh
    Nayanar, Sangeetha
    BLOOD, 2015, 126 (23)
  • [37] Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents
    Roussou, Maria
    Kastritis, Efstathios
    Christoulas, Dimitrios
    Migkou, Magdalini
    Gavriatopoulou, Maria
    Grapsa, Irini
    Psimenou, Erasmia
    Gika, Dimitra
    Terpos, Evangelos
    Dimopoulos, Meletios A.
    LEUKEMIA RESEARCH, 2010, 34 (10) : 1395 - 1397
  • [38] IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM)
    J Krönke
    F Kuchenbauer
    M Kull
    V Teleanu
    L Bullinger
    D Bunjes
    A Greiner
    S Kolmus
    S Köpff
    M Schreder
    L-O Mügge
    C Straka
    M Engelhardt
    H Döhner
    H Einsele
    F Bassermann
    R Bargou
    S Knop
    C Langer
    Leukemia, 2017, 31 : 1363 - 1367
  • [39] Reversibility of Renal Failure in Newly Diagnosed Patients with Multiple Myeloma and the Role of Novel Agents
    Roussou, Maria
    Kastritis, Efstathios
    Christoulas, Dimitrios
    Migkou, Magdalini
    Gavriatopoulou, Maria
    Matsouka, Charis
    Mparmparoussi, Despina
    Grapsa, Irini
    Psimenou, Erasmia
    Gika, Dimitra
    Terpos, Evangelos
    Dimopoulos, Meletios A.
    BLOOD, 2009, 114 (22) : 394 - 395
  • [40] BONE MARROW RETICULIN FIBROSIS AS A PROGNOSTIC MARKER IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED IN THE ERA OF NOVEL AGENTS
    Suriu, C.
    Livne, M.
    Sonkin, V.
    Akria, L.
    Barhoum, M.
    Braester, A.
    HAEMATOLOGICA, 2016, 101 : 793 - 793
12345